Mitochondrial therapies for Parkinson's disease
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is marked by widespread neurodegeneration in the brain in addition to a selective yet prominent and progressive loss of nigrostriatal dopaminergic neurons. Of the multiple theories suggested in the pathogenesis of PD, mitochondrial dysfunction takes a center stage in both sporadic and familial forms of illness. Deficits in mitochondrial functions due to impaired bioenergetics, aging associated increased generation of reactive oxygen species, damage to mitochondrial DNA, impaired calcium buffering, and alterations in mitochondrial morphology may contribute to improper functioning of the CNS leading to neurodegeneration. These mitochondrial alterations suggest that a potential target worth exploring for neuroprotective therapies are the ones that can preserve mitochondrial functions in PD. Here, we provide a recent update on potential drugs that are known to block mitochondrial dysfunctions in various experimental models and those that are currently under clinical trials for PD. We also review novel mitochondrial survival pathways that provide hope and promise for innovative neuroprotective therapies in the future that can be explored as possible therapeutic intervention for PD pathogenesis. © 2010 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.024 · Cited by 2,233
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570 · cited 1×
“Another important observation linking mitochondrial dysfunction in PD is associated with a marked age-dependent increase in mtDNA deletions in laser-captured dopaminergic neurons.(16) The deletions are clonally expanded and are associated with respiratory chain deficiencies.”
BackgroundKim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074 · cited 2×
“Of these SIRT1 is the most studied enzyme, and its activation has been demonstrated to deacetylate PGC-1a to induce mitochondrial biogenesis.67 SIRT1 activation has also shown to be protective against neurodegeneration in models of Alzheimer’s disease and ALS.68 Recently using potent pharmacological inhibitors and gen…”
BackgroundSIRT1 Functionally Interacts with the Metabolic Regulator and Transcriptional Coactivator PGC-1α
Nemoto, S., Fergusson, M. M., & Finkel, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501485200 · Cited by 1,047
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · cited 1×
“Additionally, oral administration of CoQ10 has shown very promising effects in phase II clinical trials for PD in a small group of de novo patients.(50) The Unified Parkinson’s Disease Rating Scale (UPDRS) demonstrated dose dependent reduction in disease progression without significant side effects following CoQ10 adm…”
BackgroundNutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival
Yang, H., Yang, T., Baur, J. A., Perez, E., Matsui, T., Carmona, J. J., Lamming, D. W., Souza-Pinto, N. C., Bohr, V. A., Rosenzweig, A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.035 · Cited by 950 · cited 1×
“A recent study has shown that the mammalian NAD biosynthetic enzyme Nampt (NAM phosphoribosyltransferase) can rescue cell death against genotoxic stress through the mitochondrial SIRT3 and 4 providing a link between cellular metabolism and apoptosis.(70) Although a direct correlation of mitochondrial sirtuins (SIRT3 a…”
BackgroundThomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Self-citationMartin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., & Lee, M. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4308-05.2006 · Cited by 684
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
Ekstrand, M. I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F. S., Trifunovic, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605208103 · Cited by 605 · cited 1×
“This is significant because a conditional knockout of Tfam cause progressive loss of nigrostriatal dopaminergic neurons in mice.(34) Mitochondrial localization of PD associated gene DJ-1 and its ability to impact mitochondrial functions by modulating oxidative damage induced by mitochondrial toxins further enforces th…”
BackgroundPINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1
Pridgeon, J. W., Olzmann, J. A., Chin, L.-S., & Li, L. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050172 · Cited by 596 · cited 1×
“Furthermore, PINK1, a mitochondrial kinase either due to loss of function or pathogenic mutations results in mitochondrial dysfunction and neurodegeneration due to abnormalities in mitochondrial morphology, bioenergetics, and by modulating cytochrome c release to block apoptosis in numerous in vivo and cell culture mo…”
BackgroundThe NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
BRAIN, SKELETAL MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE
MANN, V. M., COOPER, J. M., KRIGE, D., DANIEL, S. E., SCHAPIRA, A. H. V., & MARSDEN, C. D. (1992) · Brain · doi:10.1093/brain/115.2.333 · Cited by 346 · cited 1×
“Impairment of complex I activity has been detected in the substantia nigra (SN), as well as other brain regions from PD patients.(3,7,8) A systemic reduction in complex I activity”
BackgroundShults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326 · cited 1×
“Interestingly, CoQ10 levels in platelets from PD patients are reduced and it correlates with deficits in mitochondrial complex I activity.(44) CoQ10 is also known to block death due to oxidative stress,(45) apoptotic cell death by blocking Bax association with mitochondria,(46) and inhibiting mitochondrial permeabilit…”
BackgroundSelf-citationBeal, M. F., Matthews, R. T., Tieleman, A., & Shults, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01192-x · Cited by 256 · cited 9×
“Nonetheless, due to the crucial role of SIRT3 and 4 in regulation of key mitochondrial functions involved in cell death makes them an attractive thera- peutic target in treating mitochondrial dysfunction- induced neurodegeneration in PD.”
BackgroundSelf-citationBeneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders
Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., & Tarnopolsky, M. A. (2007) · Muscle & Nerve · doi:10.1002/mus.20688 · Cited by 255
Self-citationZhao, K., Luo, G., Giannelli, S., & Szeto, H. H. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.08.022 · Cited by 251 · cited 1×
“SS31 protects against oxidant-induced mitochondrial dysfunction and apoptosis in neuronal cell lines.(62) Murphy and colleagues developed the mitochondrially targeted antioxidant MitoQ (a derivative of mitochondrial quinoline) that accumulates in the mitochondria and converts hydrogen peroxide to H2O and O2, to reduce…”
BackgroundBioenergetic approaches for neuroprotection in Parkinson's disease
Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236
Self-citationBenecke, R., Strumper, P., & Weiss, H. (1993) · Brain · doi:10.1093/brain/116.6.1451 · Cited by 220 · cited 1×
“dopa dosage, and is normal in other neurodegenerative diseases, such as Multiple System Atrophy (MSA), suggesting that it is not a nonspeciıc consequence of neurodegeneration.(12,13) A number of studies provide genetic evidence that abnormalities in mtDNA (mitochondrial DNA) may contribute to PD pathogenesis.”
BackgroundMitochondrial dysfunction in Parkinson's disease
Schapira, A. H. V. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402160 · Cited by 175
Moon, Y., Lee, K. H., Park, J., Geum, D., & Kim, K. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03112.x · Cited by 174
Petri, S., Kiaei, M., Damiano, M., Hiller, A., Wille, E., Manfredi, G., Calingasan, N. Y., Szeto, H. H., & Beal, M. F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04018.x · Cited by 166
Self-citationSimon, D. K., Pulst, S. M., Sutton, J. P., Browne, S. E., Beal, M. F., & Johns, D. R. (1999) · Neurology · doi:10.1212/wnl.53.8.1787 · Cited by 141 · cited 1×
“We found Parkinsonism occurred in association with the Leber’s optic atrophy due to a point mutation G11778A in mtDNA.(15) Using laser capture micro dissection of SN dopamine neurons from early PD patients we identified that dopamine neurons harbor high levels of somatic mtDNA point mutations, particularly the subtype…”
BackgroundSelf-citationPGC-1α, a New Therapeutic Target in Huntington's Disease?
McGill, J. K., & Beal, M. F. (2006) · Cell · doi:10.1016/j.cell.2006.10.023 · Cited by 131
Self-citation
Cited by
Mitochondrial dysfunction in Parkinson's disease
Bose, A., & Beal, M. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13731 · Cited by 841
Self-citationAssessing bioenergetic function in response to oxidative stress by metabolic profiling
Dranka, B. P., Benavides, G. A., Diers, A. R., Giordano, S., Zelickson, B. R., Reily, C., Zou, L., Chatham, J. C., Hill, B. G., Zhang, J., et al. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.08.005 · Cited by 436
The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T. S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.131 · Cited by 408
Self-citationMonzio Compagnoni, G., Di Fonzo, A., Corti, S., Comi, G. P., Bresolin, N., & Masliah, E. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01926-1 · Cited by 378
Xu, M.-F., Xiong, Y.-Y., Liu, J.-K., Qian, J.-J., Zhu, L., & Gao, J. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.3 · Cited by 156
Metadata
- Authors
- Thomas, B., & Beal, M. F.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 25
- Issue
- S1
- Pages
- S155-60
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1964056794
- Cited by
- 63
- References
- 24
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.